As of December 31, 2024, Seres had $30.8 million in cash and cash equivalents. Based on the Company’s current cash, an anticipated second installment payment to be received from Nestle in July 2025, transaction-related obligations and current operating plans, the Company expects to fund operations into the first quarter of 2026.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on MCRB:
- Positive Outlook for Seres Therapeutics: FDA Endorsement and Strategic Study Design Boost Buy Rating
- Seres Therapeutics receives feedback from FDA on SER-155 development approach
- Seres Therapeutics Announces CMO Resignation in March 2025
- Seres Therapeutics Expands Board with Nestlé’s Appointee
- Seres Therapeutics announces receipt of expected $50M installment payment